Savara
IPO
Breathing new life into rare respiratory disease treatment
- Headquarters
- Austin, Texas
- Employees
- 51–200
- Founded
- 2008
- Business Model
- B2B
- Website
- savarapharma.com
- Total Funding
- $17.4M
- Last Round
- $7.4M Series BMar 2013
About
Savara Inc. (Nasdaq: SVRA) is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its lead product candidate, molgramostim inhalation solution (MOLBREEVI), is an inhaled recombinant GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease causing progressive respiratory failure.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account